Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type iib dyslipidemia with residual risk in addition to atorvastatin therapy (first) trial
Cardiovascular Drugs and Therapy,  Clinical Article

Davidson M et al. – This trial is the first to examine the effect of fenofibric acid on carotid intima–media thickness (CIMT) and the first CIMT trial to select patients with controlled low–density lipoprotein cholesterol (LDL–C) and elevated triglycerides (TG) and low high–density lipoprotein cholesterol (HDL–C) as inclusion criteria. Also, this trial will prospectively evaluate the effect of treatment on LDL particles and address shortcomings of previous CIMT trials.

  • In this multicenter, double–blind study.
  • 682 patients were randomized to once–daily delayed–release capsules of choline fenofibrate 135 mg (fenofibric acid [Trilipix; Abbott, North Chicago, IL]) or placebo plus atorvastatin treatment after a 2– to 10–week diet and atorvastatin run–in period.
  • Key inclusion criteria included age ≥45 years; posterior–wall common CIMT ≥0.7 mm on at least one side at baseline; fasting results of TG ≥150 mg/dL, and HDL–C ≤45 mg/dL for men or HDL–C ≤55 mg/dL for women at screening while receiving atorvastatin; controlled LDL–C; and known coronary heart disease (CHD) or a CHD risk equivalent.
  • The primary efficacy variable is the rate of change from baseline through week 104 in the mean posterior–wall intima–media thickness of the common carotid arteries (composite value of left and right sides).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

2 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 25, 2014    Review Article    Clinical Article

5 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

6 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

7 European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection Full Text Bristol Myers-Squibb, August 28, 2014    Free full text

8 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 11, 2014

9 Honey as an effective antimicrobial treatment for chronic wounds Full Text Chronic Wound Care Management and Research, August 21, 2014    Free full text    Review Article

10 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

11 Is the standard dose of amoxicillin-clavulanic acid sufficient? Full Text BMC Pharmacology & Toxicology, August 8, 2014    Free full text    Clinical Article

12 Acetaminophen plus ibuprofen versus opioids for treatment of post-tonsillectomy pain in children International Journal of Pediatric Otorhinolaryngology , August 18, 2014    Clinical Article

13 Update on recommendations for use of herpes zoster vaccine Full Text Morbidity and Mortality Weekly Report, August 22, 2014    Free full text

14 Comparison of new-onset gout in adults prescribed chlorthalidone vs hydrochlorothiazide for hypertension The Journal of Clinical Hypertension, September 26, 2014    Clinical Article

15 FDA approves Jardiance to treat type 2 diabetes Full Text FDA Press Announcements, August 4, 2014    Free full text

16 Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis Journal of Neurology, September 2, 2014    Evidence Based Medicine    Review Article

17 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

18 FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease Full Text FDA Press Announcements, August 1, 2014    Free full text

19 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT Journal of the American Society of Hypertension, September 15, 2014    Clinical Article

20 Digoxin tied to increased risk of death in patients with atrial fibrillation Stanford School of Medicine News, August 12, 2014

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close